Frequent capsule switching in 'ultra-virulent' meningococci - are we ready for a serogroup B ST-11 complex outbreakReport as inadecuate




Frequent capsule switching in 'ultra-virulent' meningococci - are we ready for a serogroup B ST-11 complex outbreak - Download this document for free, or read online. Document in PDF available to download.

Reference: Lucidarme, J, Lekshmi, A, Parikh, SR et al., (2017). Frequent capsule switching in 'ultra-virulent' meningococci - are we ready for a serogroup B ST-11 complex outbreak?. Journal of Infection, 75 (2), 95-103.Citable link to this page:

 

Frequent capsule switching in 'ultra-virulent' meningococci - are we ready for a serogroup B ST-11 complex outbreak?

Abstract: The meningococcal ST-11 complex (cc11) causes large invasive disease outbreaks with high case fatality rates, such as serogroup C (MenC) epidemics in industrialised nations in the 1990s and the serogroup W epidemic currently expanding globally. Glycoconjugate vaccines are available for serogroups A, C, W and Y. Broad coverage protein-based vaccines have recently been licensed against serogroup B meningococci (MenB), however, these do not afford universal MenB protection. Capsular switching from MenC to MenB among cc11 organisms is concerning because a large MenB cc11 (B:cc11) outbreak has the potential to cause significant morbidity and mortality. This study aimed to assess the potential for licensed and developmental non-capsular meningococcal vaccines to protect against B:cc11. The population structure and vaccine antigen distribution was determined for a panel of >800 geo-temporally diverse, predominantly MenC cc11 and B:cc11 genomes. The two licensed vaccines potentially protect against many but not all B:cc11 meningococci. Furthermore, strain coverage by these vaccines is often due to a single vaccine antigen and both vaccines are highly susceptible to vaccine escape owing to the apparent dispensability of key proteins used as vaccine antigens. cc11 strains with MenB and MenC capsules warrant special consideration when formulating future non-capsular meningococcal vaccines.

Publication status:PublishedPeer Review status:Peer reviewedVersion:Publisher's versionDate of acceptance:2017-05-27 Funder: Meningitis Research Foundation   Notes:This is an open access articleunder the Open Government License (OGL) (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/).

Bibliographic Details

Publisher: Elsevier

Publisher Website: https://www.elsevier.com/

Journal: Journal of Infectionsee more from them

Publication Website: https://www.journals.elsevier.com/journal-of-infection/

Volume: 75

Issue: 2

Issue Date: 2017-06-01

pages:95-103Identifiers

Doi: https://doi.org/10.1016/j.jinf.2017.05.015

Issn: 0163-4453

Eissn: 1532-2742

Uuid: uuid:68c43a7d-5d45-4aed-88d3-aade4081e809

Urn: uri:68c43a7d-5d45-4aed-88d3-aade4081e809

Pubs-id: pubs:698716 Item Description

Type: journal-article;

Language: eng

Version: Publisher's versionKeywords: Neisseria meningitidis ST-11 complex Serogroup B Vaccine meningococcal

Relationships





Author: Lucidarme, J - - - Lekshmi, A - - - Parikh, SR - - - Bray, JE - Oxford, MPLS, Zoology - - - Hill, DM - Oxford, MPLS, Zoology - -

Source: https://ora.ox.ac.uk/objects/uuid:68c43a7d-5d45-4aed-88d3-aade4081e809



DOWNLOAD PDF




Related documents